Better Science, Better Health
“Better Science, Better Health” was established by Vital Transformation to facilitate international collaboration in new clinical regulatory pathways, sources of evidence, and harnessing real world data to improve the access of needed new medicines by patients.
“Better Science, Better Health” provides a unique opportunity for international thought leaders to engage directly in these initiatives around the world, while also bringing new relevant voices into the process.
“Better Science, Better Health” has three core areas of focus:
- Harnessing real world evidence for better decision-making and create better patient outcomes
- Implementing new development pathways and evidence generation to improve access to needed new therapies for patients
- Developing best practices, successes, and opportunities for the integration of patient data and analytics to identify new medicines
Latest Events
Investing in EU Biotech IP – What Works?
4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET In this webinar we: • Highlight the results of the research • Expand on the datapackage used • Discuss the gap between EU and US IP productivity in healthcare • Address the need for IP in the global biotech sector
Supporting IP in Europe
Vital Transformation leads a new consortia investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP. This project will develop original research investigating the success factors that create successful EU biotech companies and communicate the importance of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that succeed.
DIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies
24th June 2018, Boston, USA
Duane Schulthess, Managing Director of Vital Transformation, and Luca Pani, former Director General of the Italian Medicine's Agency and currently a Faculty Member at the University of Miami, will run a 3 hour and 15 minute Short Course outlining how best to harness RWE to better understand the price, value, and impact of next generation therapies.
Latest News
US Biotech Lobby Slams EU Reference Pricing
By CARMEN PAUN 4/9/19, © POLITICO PRO Healthcare U.S. biotechnology lobby BIO said the Trump administration’s proposal to peg the prices of certain drugs to a basket of mostly EU reference countries would lead to a “downward spiral” that would negatively affect the development of new medicines.
Don’t Believe the Hype – International Reference Pricing Will Cost Far More than 1% of R&D Budgets
By Duane Schulthess
It’s odd that a city like Brussels managed to carve itself out a niche as one of the major political centres of the world. The medieval site of a notoriously typhus infested bog, one of the main streets in downtown, ‘Rue du Marais’, literally means, “Street of the Swamp” and the name of the city itself comes from the old Flemish word Broekzele, which roughly translates to ‘settlement in the swamp.’ So, when one talks politically of draining the swamp, at least in Brussels, it carries a literal interpretation that is often distant from the current political climate in DC.
The Alliance for Regenerative Medicine (ARM) supports the efforts of the Better Science Better Health IP Consortium
ARM is the leading international advocacy organization representing the gene and cell therapy sector and consists of more than 290 members, including life sciences companies, patient advocacy groups, academic research institutions, and investors.
Newsletter
Register now to receive all the latest news and events.
Latest Research
Our consultancy services
Tweets by BSBHbyVT 
Videos
Visit our youtube channel to view all of our videos.